[1] Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med,2011,208:1339-1350.
[2] Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol,2003,38 Suppl 1:S38-S53.
[3] Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med,2012,18:1028-1040.
[4] Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun,2013,4:2823.
[5] Frizell E, Liu SL, Abraham A, et al. Expression of SPARC in normal and fibrotic livers. Hepatology,1995,21:847-854.
[6] Qian H, Shi J, Fan TT, et al. Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats. World J Gastroenterol,2014,20:1822-1832.
[7] Chang J, Lan T, Li C, et al. Activation of Slit2-Robo1 signaling promotes liver fibrosis. J Hepatol,2015.
[8] Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell,2010,141:52-67.
[9] Duarte S, Baber J, Fujii T, et al. Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biology,2015,44-46:147-156.
[10] Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech,2014,7:193-203.
[11] Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol,2004,4:617-629.
[12] Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta,2013,1832:876-883.
[13] Chirco R, Liu XW, Jung KK, et al. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev,2006,25:99-113.
[14] Busk TM, Bendtsen F, Nielsen HJ, et al. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol,2014,49:1103-1110.
[15] Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest,2007,117:539-548.
[16] Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Fibrogenesis Tissue Repair,2012,5:S26.
[17] Higashi N, Senoo H. Distribution of vitamin A-storing lipid droplets in hepatic stellate cells in liver lobules--a comparative study. Anat Rec A Discov Mol Cell Evol Biol,2003,271:240-248.
[18] Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol,2013,3:1473-1492.
[19] Li Y, Jiang Y. [Update on isolation and functional research of hepatic stellate cells]. Sheng Wu Gong Cheng Xue Bao,2014,30:1059-1072.
[20] Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med,2006,10:76-99.
[21] Gressner OA, Rizk MS, Kovalenko E, et al. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? Journal of Gastroenterology and Hepatology,2008,23:1024-1035.
[22] Moses HL, Branum EL, Proper JA, et al. Transforming growth factor production by chemically transformed cells. Cancer Res,1981,41:2842-2848.
[23] Katz LH, LiY, Chen JS, et al. Targeting TGF-beta signaling in cancer. Expert Opin Ther Targets,2013,17:743-760.
[24] Kajdaniuk D, Marek B, Borgiel-Marek H, et al. Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. Endokrynologia Polska,2013,64:384-396.
[25] Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev,2000,14:627-644.
[26] Wang B, LiW, Chen Y, et al. Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis. Med Sci Monit,2012,18:R394-R401.
[27] Tu X, Zheng X, Li H, et al. MicroRNA-30 Protects Against Carbon Tetrachloride-induced Liver Fibrosis by Attenuating Transforming Growth Factor Beta Signaling in Hepatic Stellate Cells. Toxicological Sciences,2015,146:157-169.
[28] Sakai K, Jawaid S, Sasaki T, et al. Transforming growth factor-beta-independent role of connective tissue growth factor in the development of liver fibrosis.Am J Pathol, 2014,184:2611-2617.
[29] Chen J, Xia Y, Lin X, et al. Smad3 signaling activates bone marrow-derived fibroblasts in renal fibrosis. Lab Invest,2014,94:545-556.
[30] Zhang L, Liu C, Meng XM, et al. Smad2 protects against TGF-beta1/Smad3-mediated collagen synthesis in human hepatic stellate cells during hepatic fibrosis. Mol Cell Biochem,2015,400:17-28.
[31] Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology,2002,36:850-860. |
